A randomized, double-blind, placebo-controlled, parallel group clinical trial was conducted with 117 patients for 8 weeks. Patients received either Curcumin C3 Complex plus BioPerine combination or matched placebo capsules twice daily for 8 weeks. Complete lipid profile including LDL-C, non-HDL-C, Total Cholesterol, Triglyceride and Lp(a) were determined at the baseline and at end of the trial.
The study results showed significantly greater effect of curcuminoids in reducing the serum concentrations of LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a) in comparison to the placebo group. Serum HDL-C concentration was elevated significantly in the Curcuminoids group. Serum sdLDL levels were comparable in both groups at baseline and at the end of the trial. Overall effects of Curcuminoids on triglycerides, non-HDL-C, total cholesterol and Lp(a) remained significant after adjustment for baseline BMI. Curcumin C3 Complex plus BioPerine combination was well-tolerated in patients with metabolic syndrome.
This study is the first trial investigating the efficacy and safety of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome receiving standard treatment. The results of the trial supported the effectiveness of the adjunctive therapy with significant decrease in serum concentration LDL-C, non-HDL-C, total cholesterol, triglyceride, Lp(a) and elevation in serum concentration of HDL-C in patients in comparison to the standard therapy alone. The present study also encouraged the efficacy of use of co-administering BioPerine as a bioavailability enhancer.
“This research indicates additional benefits of Curcumin beyond inflammation, giving increased value to C3 Complex as the body of science grows” said Shaheen Majeed, Sabinsa marketing director. “And once again the C3 Complex and BioPerine combination has been shown to be a safe and effective supplement blend that can help keep people healthy.”
For more information: www.sabinsa.com